Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
FDA advisory panel backed approval of Grail’s Galleri multi-cancer early detection blood test for adults aged 50 and older. Panel voted 7-2, with 1 abstention, that benefits outweigh risks; safety vote was unanimous; effectiveness vote was 6-4. FDA final decision on the PMA is expected in the coming months. Disclaimer
On Wednesday, GRAIL (NASDAQ: GRAL ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary GRAIL reported a strong second quarter 2026